Aurinia Pharmaceuticals Inc was formed in April 27, 2009. The Company is a clinical stage pharmaceutical company. The Company's business is the development of a therapeutic drug to treat autoimmune diseases, in particular Lupus Nephritis, and for the prevention of graft rejection in solid organ transplant patients. Its focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of lupus nephritis. Voclosporin belongs to a class of drugs called Calcineurin Inhibitors, the cornerstone of therapy for the prevention of organ transplant rejection. The Company's operations comprise a single reporting segment engaged in the research, development and commercialization of therapeutic drugs. Its geographical areas include: Canada, United States, China and Korea.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.